Phamadule Morimatsu and WuXi XDC Achieve Milestone with Successful Shipment of ADC Modular Facilities for Singapore Manufacturing Site

On 14th October 2024, a delivery ceremony for the Singapore modular plant project, a collaboration between WuXi XDC and Pharmadule Morimatsu, was held at the Morimatsu Changshu Plant. The partnership has led to the successful delivery of state-of-the-art modular production facilities, including the first batch of nearly 100 modules, to WuXi XDC's Singapore manufacturing site. This marks a key milestone in the partnership, representing significant progress and advancing both companies’ goals in biopharmaceutical innovation.

WuXi XDC’s Singapore manufacturing facility, located in Tuas Biomedical Park, incorporates the world’s leading integrated design concept for ADC/XDC drug production. The main plant, comprising of over 200 modules supplied by Pharmadule Morimatsu, will enable seamless production of drug substances (DS) and drug products (DP) at clinical and commercial scales. The facility is also equipped with quality control (QC) laboratories, Manufacturing Science and Technology (MSAT) innovation labs, warehousing, and other essential support functions. Designed with process flexibility at its core, this state-of-the-art facility features a world-class multi-product manufacturing line, capable of meeting the full spectrum of ADC/XDC drug development and manufacturing requirements. WuXi XDC’s Singapore site is on track to be operational by late 2025.

One of the key challenges in ADC/XDC manufacturing is preventing cross-contamination while maintaining high safety standards. To address this, the facility employs special design to ensure the high quality of each batch of product and the safety of operators, meeting the stringent requirements for the production of ADCs and XDCs.

The successful shipment of this modular facility marks a significant step forward in our collaboration with Pharmadule Morimatsu, reflecting our broader vision of addressing the increasing global demand for ADC and bioconjugate therapies. It highlights our commitment to expanding world-class manufacturing capabilities while advancing our dual-sourcing strategy, ensuring our global clients have scalable access to high-quality manufacturing solutions.

“Leveraging our extensive experience in global modular facility delivery, we proudly support the development of WuXi XDC’s advanced ADC manufacturing facility in Singapore. The modular design enhances both productivity and flexibility, enabling WuXi XDC to further expand its global manufacturing capabilities. We are committed to continuing our support of WuXi XDC in advancing the construction of its Singapore site, and to collaborating further in contributing to the growth of the biopharmaceutical industry.”